For readers interested in related wellness strategies, visit our top articles on Health.HealingWell.com
These trials demonstrated its efficacy and safety in Type 2 diabetes with or without other anti-diabetic agents [42, 44,45,46,47]
It is clinical protocol supported by hard data showing that slower dose escalation dramatically reduces side effects
Cai XS, Tan ZG, Li JJ, et al
Related Stories Moderate coffee intake may support heart health, AHA says ACC introduces cardiogenic shock designation to improve heart attack care Planetary Health Diet lowers cardiovascular risk in older women Longer duration of GLP-1RA use was associated with greater risk reduction
63 Considering that T2DM and MASLD can reciprocally cause and affect each other, and given liraglutides potential therapeutic characteristics for MASLD, which may be beneficial for anti-fibrosis, more aggressive use of higher doses may bring greater clinical benefits in some groups, such as those with higher-grade fibrosis with or without T2DM